Cover Image
Market Research Report
Product code 
1070975

Biologics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Published: | IMARC Services Private Limited | 147 Pages | Delivery time: 2-3 business days

Price

Back to Top
Biologics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027
Published: April 14, 2022
IMARC Services Private Limited
Content info: 147 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

The global biologics market reached a value of US$ 294 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 501.9 Billion by 2027, exhibiting a CAGR of 9.25% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Biologics, also known as biological drugs, are disease-modifying antirheumatic drugs (DMARDs) made from living organisms or consist of components of living organisms. They include a wide variety of products, such as vaccines, blood, blood components, cells, genes, tissues, allergens, and recombinant proteins, derived from humans, animals, birds, insects, plants, and microorganisms. These products control the production of vital proteins, modify human hormones and cells, while producing substances to activate and suppress the immune system. They also change the manner of operation of natural biologic intracellular and cellular actions. In recent years, biologics have gained immense traction as they are essentially utilized to treat various diseases and conditions, including Crohn's disease, ulcerative colitis, rheumatoid arthritis and other autoimmune diseases.

Biologics Market Trends:

  • The global biologics market is primarily driven by the rising incidences and diagnosis of chronic diseases that have necessitated the availability of advanced diagnostics and treatment drugs. Biologics are genetically engineered to target a specific part of the immune system that fuels inflammation. Governments of different countries are also taking initiatives to promote the healthcare sector and ensure the availability of biologics with the onset of coronavirus disease (COVID-19). Furthermore, scientists and researchers are extensively investigating species and expression systems to enhance the productivity of biological products. Moreover, various pharmaceutical companies are undertaking research and development (R&D) activities to improve the efficacy of oral products for rheumatoid arthritis and Crohn's diseases.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global biologics market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on source, product, disease and manufacturing.
  • Breakup by Source: Microbial
  • Mammalian
  • Others

Breakup by Product:

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Proteins
  • Antisense, RNAi and Molecular Therapy
  • Others

Breakup by Disease:

  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

Breakup by Manufacturing:

  • Outsourced
  • In-House
  • Breakup by Region: North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amgen Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc. and Sanofi. Key Questions Answered in This Report:

  • How has the global biologics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global biologics market?
  • What are the key regional markets?
  • What is the breakup of the market based on the source?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the disease?
  • What is the breakup of the market based on the manufacturing?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global biologics market and who are the key players?
  • What is the degree of competition in the industry?
Product Code: SR0422A80_Report

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Biologics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Source

  • 6.1 Microbial
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Mammalian
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Monoclonal Antibodies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Vaccines
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Recombinant Proteins
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Antisense, RNAi and Molecular Therapy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Disease

  • 8.1 Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Immunological Disorders
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Cardiovascular Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Hematological Disorders
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Manufacturing

  • 9.1 Outsourced
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 In-House
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AbbVie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Amgen Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 AstraZeneca plc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 F. Hoffmann-La Roche Ltd
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 SWOT Analysis
    • 15.3.5 GlaxoSmithKline plc
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Johnson & Johnson
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck KGaA
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Novartis AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Pfizer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sanofi
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Biologics Market: Major Drivers and Challenges
  • Figure 2: Global: Biologics Market: Sales Value (in Billion US$), 2016-2021
  • Figure 3: Global: Biologics Market Forecast: Sales Value (in Billion US$), 2022-2027
  • Figure 4: Global: Biologics Market: Breakup by Source (in %), 2021
  • Figure 5: Global: Biologics Market: Breakup by Product (in %), 2021
  • Figure 6: Global: Biologics Market: Breakup by Disease (in %), 2021
  • Figure 7: Global: Biologics Market: Breakup by Manufacturing (in %), 2021
  • Figure 8: Global: Biologics Market: Breakup by Region (in %), 2021
  • Figure 9: Global: Biologics (Microbial) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 10: Global: Biologics (Microbial) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 11: Global: Biologics (Mammalian) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 12: Global: Biologics (Mammalian) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 13: Global: Biologics (Other Sources) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 14: Global: Biologics (Other Sources) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 15: Global: Biologics (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 16: Global: Biologics (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 17: Global: Biologics (Vaccines) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 18: Global: Biologics (Vaccines) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 19: Global: Biologics (Recombinant Proteins) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 20: Global: Biologics (Recombinant Proteins) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 21: Global: Biologics (Antisense, RNAi and Molecular Therapy) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 22: Global: Biologics (Antisense, RNAi and Molecular Therapy) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 23: Global: Biologics (Other Products) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 24: Global: Biologics (Other Products) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 25: Global: Biologics (Oncology) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 26: Global: Biologics (Oncology) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 27: Global: Biologics (Immunological Disorders) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 28: Global: Biologics (Immunological Disorders) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 29: Global: Biologics (Cardiovascular Disorders) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 30: Global: Biologics (Cardiovascular Disorders) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 31: Global: Biologics (Hematological Disorders) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 32: Global: Biologics (Hematological Disorders) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 33: Global: Biologics (Other Diseases) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 34: Global: Biologics (Other Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 35: Global: Biologics (Outsourced) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 36: Global: Biologics (Outsourced) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 37: Global: Biologics (In-House) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 38: Global: Biologics (In-House) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 39: North America: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 40: North America: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 41: United States: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 42: United States: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 43: Canada: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 44: Canada: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 45: Asia-Pacific: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 46: Asia-Pacific: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 47: China: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 48: China: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 49: Japan: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 50: Japan: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 51: India: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 52: India: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 53: South Korea: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 54: South Korea: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 55: Australia: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 56: Australia: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 57: Indonesia: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 58: Indonesia: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 59: Others: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 60: Others: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 61: Europe: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 62: Europe: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 63: Germany: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 64: Germany: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 65: France: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 66: France: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 67: United Kingdom: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 68: United Kingdom: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 69: Italy: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 70: Italy: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 71: Spain: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 72: Spain: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 73: Russia: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 74: Russia: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 75: Others: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 76: Others: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 77: Latin America: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 78: Latin America: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 79: Brazil: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 80: Brazil: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 81: Mexico: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 82: Mexico: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 83: Others: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 84: Others: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 85: Middle East and Africa: Biologics Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 86: Middle East and Africa: Biologics Market: Breakup by Country (in %), 2021
  • Figure 87: Middle East and Africa: Biologics Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 88: Global: Biologics Industry: SWOT Analysis
  • Figure 89: Global: Biologics Industry: Value Chain Analysis
  • Figure 90: Global: Biologics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Biologics Market: Key Industry Highlights, 2021 and 2027
  • Table 2: Global: Biologics Market Forecast: Breakup by Source (in Million US$), 2022-2027
  • Table 3: Global: Biologics Market Forecast: Breakup by Product (in Million US$), 2022-2027
  • Table 4: Global: Biologics Market Forecast: Breakup by Disease (in Million US$), 2022-2027
  • Table 5: Global: Biologics Market Forecast: Breakup by Manufacturing (in Million US$), 2022-2027
  • Table 6: Global: Biologics Market Forecast: Breakup by Region (in Million US$), 2022-2027
  • Table 7: Global: Biologics Market: Competitive Structure
  • Table 8: Global: Biologics Market: Key Players